





## PROGRAM - December 2<sup>nd</sup>

- 11.30 Registration
- 12.30 Welcome and Introduction BestPractice Nordic and NBCN Steering Committee
- 12.45 Our Ambition to Improve Breast Cancer Care in the Nordics - Kim Hjorth-Jensen, AstraZeneca
- 12.55 Imaging in Breast Cancer Malene Grubbe Hildebrandt, Marianne Vogsen
- 13.40 How Can We Collaborate to Drive Scientific Progress? - Barbro Holm, Gilead Sciences
- 13.50 Clinical Controversies in Breast Cancer Surgery-Axillary Management – Irma Frederiksson, Jana de Boniface, Tove Holst Filtenborg Tvedskov
- 14.35 Coffee Break
- 15.00 Precision Oncology in Breast Cancer Krista Heinolainen, Menarini Stemline
- **15.10** Clinical Care and Testing for Hereditary Breast Cancer in the Nordic Countries Vigdis Stefansdottir
- 15.55 Advancing Breast Cancer Research and Treatment by Collaboration in the Nordics – Lassi Liljeroos, Pfizer
- 16.05 Breast Cancer Pathology Hege Russnes
- 16.50 Reimagining Medicine Together Jenni Jarvi, Novartis
- 17.00 Introduction to "Young" Researchers NBCN Steering Committee
- 17.30 Break Personal time off
- 18.15 Poster mingle session: "Young" Researchers Presentations - Discover groundbreaking research and innovative solutions at the Poster Session, featuring over 20 compelling posters from across the Nordics

19.15 Dinner



This meeting was made possible with support from







Stemline<sup>.</sup> A Menarini Group Company U NOVARTIS

Sponsors have had no input or influence on the clinical agenda







## PROGRAM - December 3<sup>rd</sup>

- 06.30 Breakfast Served from 6:30
- 08.00 "Young" Researchers 8 minutes per country

DBCG 25R-DISCORDANT - A Randomised Trial Comparing Trastuzu ma Deruxtecan to CDK4/6 inhibitors in Non-Iuminal A, ER-positive/ HER2-low Metastatic Breast Cancer - Tobias Berg

Novel MRI-based AI Methods for Early Detectionand Personalized Treatment of Breast Cancer – Maren Andreassen

Repeat Breast Conserving Surgery and Ratiation Therapy in Recurrent Breast Cancer – Anselm Tamminen

Radioactive Seeds as a Method of Marking Positive Lymph Nodes to Perform Targeted Axillary Dissection (TAD) Post- NACT - The Helsinki Experience - Laura Salovaara

Breast Cancer in Young Patients in Iceland 2010–2023: Genetic Testing, Endocrine Therapy Compliance and Prognosis – Stefanía Katrín Finnsdóttir

Multidimensional Characterization of Immune Micro- and Macro-Environment in Neoadjuvant-Treated Early Breast Cancer Patients – *Joannis Zerdes* 

- 08.45 Radiotherapy in the Nordic Countries Birgitte Offersen
- 09.30 How Can Gene Profiling Guide Treatment Strategy? Sarah Reynia, Exact Sciences
- 09.40 Introduction of New Drugs in the Nordic Countries Minna Tanner
- 10.25 Coffee Break
- **10.40** Strategies in Collaborative Clinical Trials in the Nordic Countries *Niklas Loman* 
  - 11.15 Input for Future Nordic Clinical Network in Breast Cancer Panel
- 11.50 Key Take Home Messages NBCN Steering Committee
- 12.20 Lunch
- 13.00 Meeting with the NBCN Steering Commitee by invitation only

This meeting was made possible with support from











Stemline<sup>.</sup> A Menarini Group Company U NOVARTIS

Sponsors have had no input or influence on the clinical agenda -